Corcept Therapeutics resubmitted its New Drug Application to the FDA for relacorilant, incorporating additional data analyses requested by the agency, with an expected six-month review timeline. The resubmission is based on positive Phase III trial data showing the drug provides meaningful improvements in Cushing's syndrome symptoms with a favorable safety profile compared to existing treatments.